200 new therapies are being developed for prostate cancer

The Prostate Cancer Foundation (PCF) has announced that more than 200 new therapies are being developed for prostate cancer, many by researchers supported by the PCF. Substantially more prostate cancer therapies are in later stages of clinical development (Phases II and III) than ever before.

There are now 10 new prostate cancer therapies in Phase III clinical trials compared to only four in 1997. (Phase III clinical trials are large studies that are typically required prior to a drug receiving FDA approval.) Even more dramatically, 90 new therapies are currently in Phase II clinical trials, compared with only 31 in 1997. Information concerning prostate cancer therapies in clinical development is now available at the PCF's Prostate Cancer Therapeutics Resource Center (http://www.pcfresourcecenter.org/), part of the Prostate Cancer Foundation's newly redesigned Web site, accessible at http://www.prostatecancerfoundation.org.

Prostate Cancer Foundation CEO Leslie D. Michelson stated, "As the world's largest philanthropic source of support for prostate cancer research, we have funded some of the most promising new treatments being developed. Our newly launched website will provide patients and their families with comprehensive information on prostate cancer and its diagnosis and treatment, including up to date information on the latest treatments being developed."